Connect with us

Technology

NeuroLexIQ and Canary Speech Partner to Bring AI Voice Analysis to the Personal Injury Intake Process

Published

5 hours ago

on

New collaboration embeds Canary Speech’s vocal biomarker technology into NeuroLexIQ’s Concussion Probability Report, flagging potential brain injuries at a client’s very first contact

PROVO, Utah and KNOXVILLE, Tenn., July 15, 2026 /PRNewswire/ — Canary Speech, a leader in AI-powered voice biomarker technology, and NeuroLexIQ, The Brain Injury Authority, today announced a strategic partnership to bring objective, voice-based concussion screening into the earliest moment of a personal injury case: the client’s first intake call.

Mild traumatic brain injuries, or mTBIs, are among the most under-documented injuries in personal injury litigation. Every year, thousands of people walk away from car crashes and falls with concussions that go unseen for weeks or months. Symptoms hide, evidence fades, and clients can lose the chance to prove what happened to them. This partnership is designed to change that by giving attorneys and their clients an objective signal from the very start of a case, when it matters most.

The collaboration integrates Canary Speech’s voice analysis directly into NeuroLexIQ’s client intake workflow. During a structured intake conversation, often before any medical exam has taken place, the platform analyzes subtle patterns in a person’s speech to generate a Concussion Probability Report. When that report flags a potential injury, it opens the door to qEEG validation, pairing voice-derived signals with FDA-cleared neurodiagnostic data to build a single, litigation-ready record. 

That structure gives attorneys an objective marker captured at first contact, rather than relying solely on self-reported symptoms that can fade or become harder to substantiate over time. For clients, that means a faster, less invasive path to understanding whether further evaluation is warranted.

“For the past decade, we’ve done the hard work of turning voice into a clinically meaningful signal,” said Henry O’Connell, CEO of Canary Speech. “In personal injury cases, timing is everything. Partnering with NeuroLexIQ lets us put that signal to work at the exact moment it can do the most good.”

“By adding Canary Speech’s voice analysis to our intake process, we can objectively identify potential brain injuries from the first conversation and route the right cases for qEEG testing before symptoms fade and causation becomes harder to establish,” said Mark Slaughter, Founder & CEO of NeuroLexIQ. “It’s a meaningful step forward for how our industry documents and supports these clients.”

NeuroLexIQ and Canary Speech will begin rolling out the integrated intake process with a pilot program starting July 1, 2026, giving personal injury attorneys early access to the combined voice-and-EEG workflow.

About NeuroLexIQ
NeuroLexIQ, The Brain Injury Authority, is an independent evidence platform built to support attorneys evaluating possible brain injury cases. Through structured screening, mobile EEG diagnostics, and independent neurologist-reviewed reports, NeuroLexIQ brings clarity to potential or undiagnosed concussion cases. The company’s Concussion Probability Report analyzes crash dynamics, symptoms, and injury exposure to generate a Concussion Likelihood Score, helping determine whether additional evaluation may be warranted, while board-certified neurologists specializing in neurotrauma review every EEG under a strict chain-of-custody protocol to produce litigation-ready findings. NeuroLexIQ is not a medical provider and does not deliver treatment; it operates as an independent litigation-intelligence platform.

For more information, visit neurolexiq.com.

About Canary Speech
Canary Speech is a Utah-based, AI-powered voice biomarker health tech company, utilizing patented real-time vocal analysis to screen for mental health and neurological disorders. Canary’s technology swiftly captures and analyzes speech data, detecting behavioral and cognitive changes—including signs of anxiety, depression, and dementia—often before traditional clinical standards or noticeable symptoms. Recently, Canary Speech launched Canary Ambient™, an API-first solution for real-time voice analysis in healthcare and contact centers. This clinical decision support software provides actionable insights from patient-clinician conversations by tracking speech patterns for real-time assessments of cognitive and behavioral health conditions. Canary Speech advances speech and language applications across health systems, payers, and pharmaceutical markets.

For more information, visit canaryspeech.com.

Media Contact
Caitlyn Brooksby, VP of Marketing
Canary Speech
caitlyn@canaryspeech.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurolexiq-and-canary-speech-partner-to-bring-ai-voice-analysis-to-the-personal-injury-intake-process-302826640.html

SOURCE Canary Speech

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Club Offers for Travel Enthusiasts in Germany

Published

5 minutes ago

on

July 15, 2026

By

BERLIN, July 15, 2026 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces four of many new Club Offers for Club Members in Germany.

Rigorously vetted and negotiated for us travel enthusiasts:

FROM €2799 PP—MALDIVES: LUXURY RESORT WITH FLIGHT, SAVE €1600
7 nights, in either a beach villa or an overwater villa. All-inclusive across 5 different restaurants, with stand-up paddling, yoga, and a snorkeling trip.€89 PP—MEISSEN: HOTEL ON THE ELBE WITH CASTLE VIEWS
2 nights including breakfast in the restaurant’s winter garden. Views of the cathedral and the Albrechtsburg, Germany’s oldest castle building built in 1471.€149 PP—3 DAYS IN THE BLACK FOREST WITH 6-COURSE DINNERS, SAVE 57%
Great for hiking or cycling. Many trails start right outside the hotel, including the Baiersbronn Seensteig with its waterfalls and glacial cirque lakes. The offer includes e-bike rental and half board.FROM €309 PP—ROME, 4 DAYS, WITH FLIGHTS
Cappuccino and breakfast with a view: the 4-star hotel’s breakfast restaurant and rooftop terrace look out over St. Peter’s Basilica. Twenty minutes’ walk to the Spanish Steps and the Trevi Fountain.

Offers have limited inventory and are subject to availability.

Are you a travel enthusiast? Join the club today: https://travelzoo.com

Who are we?
We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel companies give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a modern travel enthusiast.

Travelzoo
Unter den Linden 40
10117 Berlin

Media Contact: 
Natalia Cwierz – Berlin
+49 30 311 975 20
ncwierz@travelzoo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/club-offers-for-travel-enthusiasts-in-germany-302826182.html

SOURCE Travelzoo

Continue Reading

Technology

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Published

1 hour ago

on

July 15, 2026

By

WASHINGTON, July 15, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.

The partnership aligns NEREUS’™ breakthrough innovation in motion relief with the high-speed world of IndyCar racing, where focus and stability are essential.

This sponsorship marks a symbolic milestone: 47 years since the last new motion sickness treatment was introduced in the United States. NEREUS™ represents a modern advancement as a selective NK-1 receptor antagonist designed to prevent vomiting induced by motion, offering a new option for millions who experience motion sickness during travel.

“Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions,” said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda. 

The NEREUS™-branded No. 47 IndyCar will feature prominent sponsorship visibility across select NTT IndyCar Series events in 2026.

About NEREUS™ (tradipitant)

NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About Rahal Letterman Lanigan Racing

Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-powers-forward-sponsors-no-47-indycar-entry-celebrating-47-years-since-last-new-us-motion-sickness-treatment-302826721.html

SOURCE Vanda Pharmaceuticals Inc.

Continue Reading

Technology

VIAVI Announces Date for Fiscal Fourth Quarter and Fiscal Year 2026 Financial Results

Published

1 hour ago

on

July 15, 2026

By

CHANDLER, Ariz., July 15, 2026 /PRNewswire/ — Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) will announce its fiscal fourth quarter and fiscal year 2026 financial results for the period ended June 27, 2026, on Wednesday, August 5, 2026, after the close of market.

The Company will host an earnings call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the call and the replay will be available on the VIAVI website at https://investor.viavisolutions.com. The quarterly earnings press release, supplementary slides and historical financial tables will be posted under the “Quarterly Results” section.

To participate via telephone:

Toll-Free Dial-In Number:

1 (833) 461-5787

Toll Dial-In Number:

1 (585) 542-9983

Conference ID:

687 725 628

About VIAVI Solutions
VIAVI (NASDAQ: VIAV) is a global leader in test and measurement and optical technologies. Our test, monitoring, assurance, and resilient position, navigation and timing solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, we develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets.

Learn more about VIAVI at www.viavisolutions.com. Follow us on VIAVI Perspectives, LinkedIn and YouTube.

Investors Contact:
Vibhuti Nayar, 408-404-6305; investor.relations@viavisolutions.com
Press Contact:
Amit Malhotra, 202-341-8624; amit.malhotra@viavisolutions.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viavi-announces-date-for-fiscal-fourth-quarter-and-fiscal-year-2026-financial-results-302822275.html

SOURCE VIAVI Financials

Continue Reading

Trending